Lupus nephritis secondary prevention

	Lupus nephritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Lupus nephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Lupus nephritis secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lupus nephritis secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lupus nephritis secondary prevention
CDC on Lupus nephritis secondary prevention
Lupus nephritis secondary prevention in the news
Blogs on Lupus nephritis secondary prevention
Directions to Hospitals Treating Lupus nephritis
Risk calculators and risk factors for Lupus nephritis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]

Overview

Secondary prevention strategies following systemic lupus erythematosus include using aspirin, ACE inhibitors, and statins to reduce atherosclerotic diseases, and using cancer screenings.

Aims of secondary prevention measures for SLE include:^[1]^[2]

Preventing glucocorticoid usage and using the minimum dosage to prevent osteonecrosis and osteoprosis side effects
Decreasing atherosclerotic events in patients
- Low doses of aspirin
- ACE inhibitors
- Statins
For prevention and/or early diagnosis of malignancies:
- Regular age-related specific cancer screening recommended for the general population

↑ Maidhof W, Hilas O (April 2012). "Lupus: an overview of the disease and management options". P T. 37 (4): 240–9. PMC 3351863. PMID 22593636.
↑ Zangger P, Gladman DD, Urowitz MB, Bogoch ER (2000). "Outcome of total hip replacement for avascular necrosis in systemic lupus erythematosus". J. Rheumatol. 27 (4): 919–23. PMID 10782816.